Hays Advisory’s PDL BioPharma, Inc. PDLI Stock Holding History

Hays Advisory’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-255	Closed	-$1K	–	153
2018 Q1	$1K	Buy	+255	New	+$696	﹤0.01%	142
2016 Q1	–	Sell	-887,214	Closed	-$3.14M	–	76
2015 Q4	$3.14M	Sell	887,214 -144,326	-14%	-$604K	0.53%	47
2015 Q3	$5.19M	Sell	1,031,540 -6,060	-0.6%	-$34.7K	0.78%	43
2015 Q2	$6.67M	Sell	1,037,600 -82,194	-7%	-$551K	0.97%	44
2015 Q1	$7.88M	Buy	1,119,794 +12,096	+1%	+$87.6K	1.02%	47
2014 Q4	$8.54M	Sell	1,107,698 -190,761	-15%	-$1.51M	1.14%	41
2014 Q3	$9.7M	Buy	+1,298,459	New	+$12.1M	1.28%	37

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Hays Advisory's PDLI Position: Q2 2018 in Review

Hays Advisory sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 255 shares — an estimated $1K sold.

Hays Advisory first reported a position in PDLI in Q3 2014 and held it in 7 quarters. The position peaked at $9.7M in Q3 2014. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Hays Advisory reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Hays Advisory sold 255 PDL BioPharma, Inc. shares in Q2 2018, an estimated $1K.
Hays Advisory first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 7 quarters.
Hays Advisory's PDL BioPharma, Inc. position peaked at $9.7M in Q3 2014.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Hays Advisory's 13F filing for Q2 2018, filed 23 Jul 2018.